TROG 04.01 - Cavilon Breast - TROG Cancer Research

By w.paterson
14 August, 2021
0 Comments

A Paired Double Blind Randomised Comparison of Cavilon Durable Barrier Cream (CDBC) to 10% Glycerine (“Sorbolene”) Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care.

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Clinical Trial Registration

Registration Link

Tour de Cure grants for TROG Cancer Research trials

9 January, 2025

Tour de Cure grants support two valuable TROG trials

9 January 2025: Two important TROG Cancer Research trials

7 January, 2025

GenesisCare Foundation $300,000 donation to support TROG work

7 January 2025: TROG Cancer Research is advancing vital

Earlybird registration closes 26 January.

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Paired Double Blind Randomised Comparison of Cavilon Durable Barrier Cream (CDBC) to 10% Glycerine (“Sorbolene”) Cream in the Prophylactic Management of Post-Mastectomy Irradiation Skin Care.

TROG 01.02 – PCNSL

NCIC CTG SC.20/TROG 03.08/BONEMETS

Related Post

Tour de Cure grants support two valuable TROG trials

GenesisCare Foundation $300,000 donation to support TROG work